Open Access. Powered by Scholars. Published by Universities.®

Bioinformatics Commons

Open Access. Powered by Scholars. Published by Universities.®

Genomics

Dissertations & Theses (Open Access)

Tumor Microenvironment

Publication Year

Articles 1 - 2 of 2

Full-Text Articles in Bioinformatics

Investigating The Ecology And Evolution Of Normal Breast Tissues And Breast Cancer With Single Cell Genomics, Tapsi Kumar, Tapsi Kumar May 2022

Investigating The Ecology And Evolution Of Normal Breast Tissues And Breast Cancer With Single Cell Genomics, Tapsi Kumar, Tapsi Kumar

Dissertations & Theses (Open Access)

There is vast cellular heterogeneity in human breast tissues, with different transcriptional programs in the stromal, epithelial, and immune components, however, it remains unclear how their reprogramming and interplay leads to the progression of invasive phenotypes such as Triple- Negative Breast cancer (TNBC). To do define the microenvironmental alterations that occur during cancer, we first established a human breast cell atlas, a reference of normal breast cell types from disease free women. We profiled 535,941 cells from 62 women and 124,024 nuclei from 20 women revealing 11 major cell types and 52 cell states that reflect different biological functions that …


Impact Of Intratumor Heterogeneity And The Tumor Microenvironment In Shaping Tumor Evolution And Response To Therapy, Akash Mitra Jun 2021

Impact Of Intratumor Heterogeneity And The Tumor Microenvironment In Shaping Tumor Evolution And Response To Therapy, Akash Mitra

Dissertations & Theses (Open Access)

Intratumor heterogeneity (ITH) is a crucial challenge in cancer treatment. The genotypic and phenotypic heterogeneity underlying diverse cancer types leads to subclonal variation, which may result in mixed or failed response to therapy. The heterogeneity at the tumor level, along with the tumor microenvironment (TME), often shapes tumor evolution and ultimately clinical outcome. Given that modern treatment paradigms increasingly expose patients with metastatic disease to multiple treatment modalities through the course of their disease, there exists a need to characterize robust and predictive biomarkers of response to therapy. In order to accurately characterize tumor evolution, we need to account for …